PE20220487A1 - Anticuerpos anti-ms4a4a y metodos de uso de los mismos - Google Patents
Anticuerpos anti-ms4a4a y metodos de uso de los mismosInfo
- Publication number
- PE20220487A1 PE20220487A1 PE2022000171A PE2022000171A PE20220487A1 PE 20220487 A1 PE20220487 A1 PE 20220487A1 PE 2022000171 A PE2022000171 A PE 2022000171A PE 2022000171 A PE2022000171 A PE 2022000171A PE 20220487 A1 PE20220487 A1 PE 20220487A1
- Authority
- PE
- Peru
- Prior art keywords
- region
- hvr
- seq
- group
- amino acid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Abstract
Referida a un anticuerpo aislado que se une a una proteina MS4A4A, donde el anticuerpo comprende una region variable de cadena pesada y una region variable de cadena ligera, donde la region variable de cadena pesada comprende: una region HVR-H1 que comprende una secuencia de aminoacidos seleccionados de entre los grupos que consisten en los SEQ ID NO: 94, 108, 116, 146, 147, 308, y 311; una region HVR-H2 que comprende una secuencia de aminoacidos seleccionada del grupo que consiste en los SEQ ID NO:96, 97, 98, 99, 110, 111, 118, 119, 120, 121, 122, 149, 150, 151, 152, 153, 309, y 312; y una region HVR-H3 que comprende una secuencia de aminoacidos seleccionada de entre el grupo que consiste en los SEQ ID NO: 102, 100, 101, 102, 112, 123, 124, 125, 126, 127, 128, 129, 154, 310, y 313; y la region variable de cadena ligera comprende: una region HVR-L1 que comprende una secuencia de aminoacidos seleccionados del grupo que consiste en SEQ ID NO: 104, 103, 113, 130, 131, 132, 133, 134, 135, 136, 137, 138, 156, 157, 158, 314, y 317; una region HVR-L2 que comprende una secuencia de aminoacidos seleccionada de entre el grupo que consiste en SEQ ID NO.: 105, 106, 114, 139, 140, 141, 142, 143, 159, 160, 161, 315, y 318; y una region HVR-L3 que comprende una secuencia de aminoacidos seleccionada de entre el grupo que consiste en los SEQ ID NO:107, 115, 144, 145, 163, 316, y 319. Tambien esta referida a composiciones que comprenden los mencionados anticuerpos. Dicho anticuerpo es util en el tratamiento de enfermedades neurodegenerativas.
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962881187P | 2019-07-31 | 2019-07-31 | |
US201962892467P | 2019-08-27 | 2019-08-27 | |
US201962947449P | 2019-12-12 | 2019-12-12 | |
US202062960606P | 2020-01-13 | 2020-01-13 | |
US202063057142P | 2020-07-27 | 2020-07-27 | |
PCT/US2020/044335 WO2021022083A2 (en) | 2019-07-31 | 2020-07-30 | Anti-ms4a4a antibodies and methods of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20220487A1 true PE20220487A1 (es) | 2022-04-04 |
Family
ID=72139691
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2022000171A PE20220487A1 (es) | 2019-07-31 | 2020-07-30 | Anticuerpos anti-ms4a4a y metodos de uso de los mismos |
Country Status (17)
Country | Link |
---|---|
US (2) | US11667699B2 (es) |
EP (1) | EP4003519A2 (es) |
JP (1) | JP2022542964A (es) |
KR (1) | KR20220058540A (es) |
CN (1) | CN114341181A (es) |
AU (1) | AU2020321969A1 (es) |
BR (1) | BR112022001733A2 (es) |
CA (1) | CA3145885A1 (es) |
CL (1) | CL2022000230A1 (es) |
CO (1) | CO2022000832A2 (es) |
CR (1) | CR20220078A (es) |
EC (1) | ECSP22015044A (es) |
IL (1) | IL289952A (es) |
MX (1) | MX2022001260A (es) |
PE (1) | PE20220487A1 (es) |
TW (1) | TW202120547A (es) |
WO (1) | WO2021022083A2 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019152715A1 (en) | 2018-01-31 | 2019-08-08 | Alector Llc | Anti-ms4a4a antibodies and methods of use thereof |
CA3145885A1 (en) | 2019-07-31 | 2021-02-04 | Jeonghoon Sun | Anti-ms4a4a antibodies and methods of use thereof |
WO2024026447A1 (en) * | 2022-07-29 | 2024-02-01 | Alector Llc | Anti-gpnmb antibodies and methods of use thereof |
WO2024026472A2 (en) * | 2022-07-29 | 2024-02-01 | Alector Llc | Transferrin receptor antigen-binding domains and uses therefor |
Family Cites Families (74)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
EP0206448B1 (en) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
KR0184860B1 (ko) | 1988-11-11 | 1999-04-01 | 메디칼 리써어치 카운실 | 단일영역 리간드와 이를 포함하는 수용체 및 이들의 제조방법과 이용(법) |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
ATE158021T1 (de) | 1990-08-29 | 1997-09-15 | Genpharm Int | Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
ATE164395T1 (de) | 1990-12-03 | 1998-04-15 | Genentech Inc | Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften |
US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
LU91067I2 (fr) | 1991-06-14 | 2004-04-02 | Genentech Inc | Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines |
GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
EP0604580A1 (en) | 1991-09-19 | 1994-07-06 | Genentech, Inc. | EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
US5869619A (en) | 1991-12-13 | 1999-02-09 | Xoma Corporation | Modified antibody variable domains |
ES2202310T3 (es) | 1991-12-13 | 2004-04-01 | Xoma Corporation | Metodos y materiales para la preparacion de dominios variables de anticuerpos modificados y sus usos terapeuticos. |
DE69333807T2 (de) | 1992-02-06 | 2006-02-02 | Chiron Corp., Emeryville | Marker für krebs und biosynthetisches bindeprotein dafür |
US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
WO1997011971A1 (en) | 1995-09-28 | 1997-04-03 | Alexion Pharmaceuticals, Inc. | Porcine cell interaction proteins |
US6133426A (en) | 1997-02-21 | 2000-10-17 | Genentech, Inc. | Humanized anti-IL-8 monoclonal antibodies |
US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
US6610833B1 (en) | 1997-11-24 | 2003-08-26 | The Institute For Human Genetics And Biochemistry | Monoclonal human natural antibodies |
DK1034298T3 (da) | 1997-12-05 | 2012-01-30 | Scripps Research Inst | Humanisering af murint antistof |
GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
KR100797667B1 (ko) | 1999-10-04 | 2008-01-23 | 메디카고 인코포레이티드 | 외래 유전자의 전사를 조절하는 방법 |
US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
LT2857516T (lt) | 2000-04-11 | 2017-09-11 | Genentech, Inc. | Multivalentiniai antikūnai ir jų panaudojimas |
US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
US7064191B2 (en) | 2000-10-06 | 2006-06-20 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
US7041870B2 (en) | 2000-11-30 | 2006-05-09 | Medarex, Inc. | Transgenic transchromosomal rodents for making human antibodies |
AU2002251692A1 (en) | 2000-12-08 | 2002-08-19 | Duke University | Identification of novel ms4a gene family members expressed by hematopoietic cells |
WO2003035835A2 (en) | 2001-10-25 | 2003-05-01 | Genentech, Inc. | Glycoprotein compositions |
US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
ES2362419T3 (es) | 2002-04-09 | 2011-07-05 | Kyowa Hakko Kirin Co., Ltd. | Células con depresión o deleción de la actividad de la proteína que participa en el transporte de gdp-fucosa. |
CA2481837A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Production process for antibody composition |
WO2003084569A1 (fr) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Medicament contenant une composition anticorps |
PL373256A1 (en) | 2002-04-09 | 2005-08-22 | Kyowa Hakko Kogyo Co, Ltd. | Cells with modified genome |
GB0324888D0 (en) * | 2003-10-24 | 2003-11-26 | Novartis Ag | Organic compounds |
ZA200608130B (en) | 2004-03-31 | 2008-12-31 | Genentech Inc | Humanized anti-TGF-beta antibodies |
KR20070034588A (ko) | 2004-06-14 | 2007-03-28 | 더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈 | Cd34+/cd36+ 태아 세포에는 결합하지만 성체세포에는 결합하지 않는 항체 |
US7700099B2 (en) | 2005-02-14 | 2010-04-20 | Merck & Co., Inc. | Non-immunostimulatory antibody and compositions containing the same |
CA3022097C (en) | 2006-03-15 | 2020-10-27 | Alexion Pharmaceuticals, Inc. | Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement |
EP2016101A2 (en) | 2006-05-09 | 2009-01-21 | Genentech, Inc. | Binding polypeptides with optimized scaffolds |
US10118970B2 (en) | 2006-08-30 | 2018-11-06 | Genentech, Inc. | Multispecific antibodies |
GB0624500D0 (en) * | 2006-12-07 | 2007-01-17 | Istituto Superiore Di Sanito | A novel passive vaccine for candida infections |
UY30776A1 (es) | 2006-12-21 | 2008-07-03 | Medarex Inc | Anticuerpos cd44 |
CN100592373C (zh) | 2007-05-25 | 2010-02-24 | 群康科技(深圳)有限公司 | 液晶显示面板驱动装置及其驱动方法 |
ES2774337T3 (es) | 2008-01-07 | 2020-07-20 | Amgen Inc | Método para fabricación de moléculas heterodímeras Fc de anticuerpos utilizando efectos de conducción electrostática |
EP2108701A1 (en) * | 2008-04-10 | 2009-10-14 | Ganymed Pharmaceuticals AG | Methods involving MS4A12 and agents targeting MS4A12 for therapy, diagnosis and testing |
UA116192C2 (uk) | 2011-08-23 | 2018-02-26 | Рош Глікарт Аг | Активуюча т-клітини біоспецифічна антигензв'язуюча молекула |
CN104774264B (zh) | 2014-01-15 | 2018-09-14 | 上海易乐生物技术有限公司 | 抗人proBDNF单克隆抗体及其在疼痛中的作用 |
CA2874083C (en) * | 2014-12-05 | 2024-01-02 | Universite Laval | Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases |
WO2017143036A1 (en) | 2016-02-16 | 2017-08-24 | President And Fellows Of Harvard College | Modulators of ms4a activity |
CN105759057A (zh) | 2016-04-12 | 2016-07-13 | 上海凯璟生物科技有限公司 | 一种检测阿尔兹海默综合症ms4a6a的干式免疫荧光试剂盒和制备方法 |
CN112204050A (zh) | 2018-01-31 | 2021-01-08 | 艾莱克特有限责任公司 | 抗ms4a6a抗体及其使用方法 |
WO2019152715A1 (en) | 2018-01-31 | 2019-08-08 | Alector Llc | Anti-ms4a4a antibodies and methods of use thereof |
CA3145885A1 (en) | 2019-07-31 | 2021-02-04 | Jeonghoon Sun | Anti-ms4a4a antibodies and methods of use thereof |
-
2020
- 2020-07-30 CA CA3145885A patent/CA3145885A1/en active Pending
- 2020-07-30 US US16/943,123 patent/US11667699B2/en active Active
- 2020-07-30 MX MX2022001260A patent/MX2022001260A/es unknown
- 2020-07-30 JP JP2022506146A patent/JP2022542964A/ja active Pending
- 2020-07-30 AU AU2020321969A patent/AU2020321969A1/en active Pending
- 2020-07-30 TW TW109125889A patent/TW202120547A/zh unknown
- 2020-07-30 PE PE2022000171A patent/PE20220487A1/es unknown
- 2020-07-30 WO PCT/US2020/044335 patent/WO2021022083A2/en unknown
- 2020-07-30 CR CR20220078A patent/CR20220078A/es unknown
- 2020-07-30 BR BR112022001733A patent/BR112022001733A2/pt unknown
- 2020-07-30 KR KR1020227006203A patent/KR20220058540A/ko unknown
- 2020-07-30 CN CN202080062076.0A patent/CN114341181A/zh active Pending
- 2020-07-30 EP EP20757743.8A patent/EP4003519A2/en active Pending
-
2022
- 2022-01-18 IL IL289952A patent/IL289952A/en unknown
- 2022-01-28 CL CL2022000230A patent/CL2022000230A1/es unknown
- 2022-01-28 CO CONC2022/0000832A patent/CO2022000832A2/es unknown
- 2022-02-25 EC ECSENADI202215044A patent/ECSP22015044A/es unknown
-
2023
- 2023-05-01 US US18/310,207 patent/US20240076362A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20240076362A1 (en) | 2024-03-07 |
WO2021022083A3 (en) | 2021-03-11 |
AU2020321969A1 (en) | 2022-03-17 |
JP2022542964A (ja) | 2022-10-07 |
CN114341181A (zh) | 2022-04-12 |
US11667699B2 (en) | 2023-06-06 |
CA3145885A1 (en) | 2021-02-04 |
CR20220078A (es) | 2022-06-24 |
EP4003519A2 (en) | 2022-06-01 |
TW202120547A (zh) | 2021-06-01 |
ECSP22015044A (es) | 2022-03-31 |
IL289952A (en) | 2022-03-01 |
US20210079074A1 (en) | 2021-03-18 |
CL2022000230A1 (es) | 2022-10-07 |
BR112022001733A2 (pt) | 2022-06-28 |
WO2021022083A2 (en) | 2021-02-04 |
CO2022000832A2 (es) | 2022-04-29 |
KR20220058540A (ko) | 2022-05-09 |
MX2022001260A (es) | 2022-04-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20220487A1 (es) | Anticuerpos anti-ms4a4a y metodos de uso de los mismos | |
PE20201186A1 (es) | Anticuerpos antitau y metodos de uso | |
PE20181336A1 (es) | Anticuerpos que se unen a interleucina 8 (il-8) y sus usos | |
PE20210342A1 (es) | Anticuerpos anti-sirpa y metodos de utilizacion de los mismos | |
PE20190630A1 (es) | Anticuerpos de anti-tim-3 | |
JP2020500538A5 (es) | ||
AR102594A1 (es) | ANTICUERPOS ANTI-IL-1b Y MÉTODOS DE USO | |
PE20161571A1 (es) | Anticuerpos anti-ox40 y metodos de uso | |
PE20181363A1 (es) | Variantes optimizadas de anticuerpos anti-vegf | |
ES2685424T3 (es) | Anticuerpos anti-Jagged1 y procedimientos de uso | |
PE20191208A1 (es) | Anticuerpos anti-cd73 y usos de los mismos | |
PE20200294A1 (es) | Anticuerpos que se unen especificamente a pd-1 y metodos de uso | |
PE20211863A1 (es) | Moleculas de union a antigeno biespecificas que comprenden el clon 212 anti-fap | |
AR126019A1 (es) | Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación | |
PE20170935A1 (es) | Anticuerpos anti-her2 e inmunoconjugados | |
PE20212088A1 (es) | Anticuerpos anti-tau y uso de los mismos | |
PE20120553A1 (es) | Anticuerpos anti-fgfr3 | |
AR103713A1 (es) | Anticuerpos contra tau y sus usos | |
PH12018500708A1 (en) | Humanized anti-human cd19 antibodies and methods of use | |
PE20181270A1 (es) | Anticuerpo que neutraliza el virus respiratorio sincitial humano | |
ES2628108T3 (es) | Anticuerpos multiespecíficos | |
RS53942B1 (en) | Antibodies and Immunoconjugates and Their Use | |
AR069501A1 (es) | Anticuerpos anti- vegf (factor de crecimiento endotelial vascular) | |
AR102592A1 (es) | Anticuerpos biespecíficos y métodos de uso en oftalmología | |
AR099855A1 (es) | Anticuerpos hemaglutinina del virus antiinfluenza b y métodos de uso |